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ABSTRACT
Filamin A interacting protein 1-like (FILIP1L) is an inhibitor of the canonical 
WNT pathway. WNT/β-catenin signaling and its downstream pathway, epithelial-
to-mesenchymal transition (EMT), play a key role in ovarian cancer metastasis and 
chemoresistance.  To study the clinical implications of FILIP1L in regulating the 
WNT/β-catenin pathway, the expression of FILIP1L, β-catenin, SNAIL and SLUG was 
analyzed by immunohistochemistry on tissue microarrays of 369 ovarian samples 
ranging from normal to metastatic. In addition, the results were validated in mouse 
model and in vitro cell culture. In the present study, we demonstrated that FILIP1L 
expression was inversely correlated with poor prognosis, stage and chemoresistance in 
ovarian cancer. Notably, low FILIP1L expression was independent negative prognostic 
factor with respect to overall and disease-free survival. FILIP1L inhibited peritoneal 
metastases in orthotopic mouse model. FILIP1L knockdown induced chemoresistance 
in ovarian cancer cells and this phenotype was rescued by simultaneous knockdown 
of FILIP1L and SLUG, an EMT activator. We also demonstrated that FILIP1L regulates 
β-catenin degradation. FILIP1L co-localizes with phospho-β-catenin and increases 
phospho-β-catenin at the centrosomes, destined for proteosomal degradation. Finally, 
we showed that FILIP1L regulates EMT. Overall, these findings suggest that FILIP1L 
promotes β-catenin degradation and suppresses EMT, thereby inhibiting metastases 
and chemoresistance. Our study provides the first clinical relevance of FILIP1L 
in human cancer, and suggests that FILIP1L may be a novel prognostic marker 
for chemotherapy in ovarian cancer patients. Further, the modulation of FILIP1L 
expression may have the potential to be a target for cancer therapy.
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INTRODUCTION
Ovarian cancer is the most general cause of death 
from gynecological cancers and the fifth leading cause of 
death from all cancers in women [1]. Most patients are 
diagnosed with advanced stage metastatic disease [1]. 
Following surgical cytoreduction, the standard cytotoxic 
systemic regimens consist of platinum and a taxane, and 
most patients attain initial complete clinical remission [2]. 
The majority of them, however, will eventually have a 
relapse and die of their disease [2, 3]. The overall survival 
rate, while improved by recent advances in targeted 
therapy, remains poor, with the five-year survival rate 
below 25% for stage III-IV disease [1, 4]. Thus, a better 
understanding of the pathways involved in metastasis and 
chemoresistance is crucial for the development of more 
effective therapies in ovarian cancer.
There is abundant, published evidence for the 
central role of WNT signaling in ovarian cancer biology 
[5–9]. The canonical WNT signaling leads to the nuclear 
accumulation of β-catenin and transcriptional activation 
of target genes [10]. Genetic and epigenetic deregulation 
of various steps of WNT signaling results in metastasis 
and chemoresistance in ovarian cancer [7–9]. Increased 
β-catenin levels are commonly observed in different 
ovarian cancer subtypes and correlate with cancer stage 
and poor survival [6, 11–14]. 
The WNT/β-catenin signaling pathway was first 
described for its role in carcinogenesis and later shown to 
regulate epithelial-to-mesenchymal transition (EMT) during 
embryogenesis [15]. As a result of EMT, epithelial cells 
gain a pluripotent mesenchymal phenotype, featured by 
loss of cell adhesion, acquisition of mesenchymal markers, 
increased cell motility and resistance to programmed 
cell death [16]. In cancer, the properties of mesenchymal 
cells directly contribute to their enhanced invasiveness 
and chemoresistance [17]. Key regulators of EMT are 
up-regulated by WNT/β-catenin signaling, including 
transcription factors SNAIL, SLUG, ZEB and TWIST 
[16,18]. Activation of WNT/β-catenin signaling is linked 
to initiation of EMT in ovarian cancer cells [8, 12, 19–23].
The loss of E-cadherin, a key feature of EMT, 
occurs in most carcinomas, and facilitates metastasis 
[24]. EMT has been involved in ovarian cancer metastasis 
[25, 26]. However, a unique characteristic of ovarian 
cancer is that primary differentiated carcinomas gain 
E-cadherin expression compared to the mesenchymally-
driven normal ovarian surface epithelium [27, 28]. 
Subsequent regain of mesenchymal characteristics has 
been observed in more advanced tumors with associated 
loss of E-cadherin expression during metastatic 
progression [28–30]. Despite the dual expression pattern 
of E-cadherin in ovarian cancer progression, its expression 
is related with longer survival in the most of studies with 
clinical ovarian carcinoma specimens [25, 31, 32]. Forced 
expression of E-cadherin results in inhibition of ovarian 
cancer metastasis [33]. In contrast, the expression of 
mesenchymal markers such as N-cadherin, SNAIL and 
TWIST is associated with poor prognosis [25, 34, 35]. 
Molecular expression profiles from clinical samples also 
support the role of EMT in chemoresistance [36, 37] as 
well as metastasis [12, 38] in ovarian cancer. Inhibiting 
EMT-like events is therefore a reasonable therapeutic 
strategy for combating ovarian cancer progression. 
Filamin A interacting protein 1-like (FILIP1L) 
inhibits the canonical WNT pathway [39]. Its inhibition by 
FILIP1L results in the transcriptional down-regulation of 
WNT target genes, leading to the inhibition of cell invasion 
and metastasis [39]. We originally observed that FILIP1L 
was down-regulated through promoter methylation, and 
its down-regulation induced an invasive phenotype in 
various types of cancer cells including ovarian [39–42]. 
Modulation of FILIP1L expression in these cancer cells 
led to the changes in cell invasion [39–41]. We also 
demonstrated FILIP1L has an anti-angiogenic function 
that over-expression of FILIP1L in endothelial cells led to 
decreased cell migration and increased apoptosis, and that 
tumor vessel-expression of FILIP1L blocked in vivo tumor 
growth [42]. FILIP1L appears to be widely expressed in 
human tissues and its physiologic function is currently not 
known. There are five known isoforms of FILIP1L that 
are generated by alternative splicing; our work focuses on 
the most prevalent isoform 2 [40, 43, 44]. Its structural 
homologies and centrosomal localization suggest that 
FILIP1L may bind elements of the cytoskeleton and 
chaperone proteins to proteasomes [39, 43, 45]. However, 
the clinical relevance of FILIP1L down-regulation in 
cancer progression has yet to be addressed.
In this study, we show that FILIP1L is a marker of 
prognosis, stage and chemosensitivity in ovarian cancer. 
FILIP1L knockdown induces chemoresistance in ovarian 
cancer cells. Moreover, the tumor-suppressor activity of 
FILIP1L is exerted through its inhibition of EMT, a mechanism 
of metastasis and chemoresistance in ovarian cancer. 
RESULTS
FILIP1L is a marker of prognosis, stage and 
chemosensitivity in ovarian cancer
We previously showed that FILIP1L inhibits the 
canonical WNT pathway by reducing nuclear β-catenin 
amount and β-catenin-directed transcriptional activity 
[39]. As described earlier, the WNT/β-catenin pathway and 
its downstream target pathway EMT has been implicated 
in ovarian cancer metastasis and chemoresistance. In 
particular, EMT-regulating transcription factors SLUG and 
SNAIL were shown to be directly associated with cisplatin 
and paclitaxel resistance in ovarian cancer [46, 47]. To 
study the clinical implications of FILIP1L in regulating 
the WNT/β-catenin pathway and chemoresistance, 
we examined the expression of FILIP1L, β-catenin, 
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SNAIL and SLUG in ovarian cancer specimens from 
patients in whom clinical outcome data were available. 
Immunohistochemical staining on tissue microarrays of 
ovarian samples ranging from normal to metastatic were 
performed. The clinicopathological features of the study 
are detailed in Table 1. We showed that loss of FILIP1L 
expression increases with tumor progression, resulting in 
a significant difference between primary and metastatic 
ovarian cancer samples, whereas the levels of β-catenin 
and SLUG increase with tumor progression (Figure 
1A, 1B and Supplementary Figure S1A). As shown 
in Supplementary Figure S2, FILIP1L expression was 
significantly decreased in metastatic tissues compared with 
primary ovarian cancer tissues from matching patients. 
There were no differences in these protein levels between 
Serous and other ovarian cancer histologies (Table 1). 
Further substantiating the inverse relationship between 
FILIP1L levels and tumor progression was the difference 
in its expression between early and late stage ovarian 
cancer (Figure 1C). Importantly, tumors that were resistant 
to platinum/paclitaxel combination therapy showed 
a significant reduction in FILIP1L expression when 
compared to sensitive tumors (Figure 1D). In contrast, 
SLUG expression was significantly higher in resistant 
tumors than in sensitive tumors (Supplementary Figure 
S1C). FILIP1L expression was correlated negatively 
with the expression of β-catenin and SLUG, whereas 
β-catenin expression was correlated positively with SLUG 
expression, suggesting a link between FILIP1L and the 
WNT/β-catenin pathway in ovarian cancer (Supplementary 
Figure S1D). Although expression of SNAIL increased 
with tumor progression, it was not different between 
chemo-resistant and chemo-sensitive tumors, nor was there 
a negative correlation with the expression of FILIP1L (data 
not shown; a representative image of immunohistochemical 
staining of SNAIL is shown in Supplementary Figure S3). 
We next examined the relationship between the 
expression levels of these proteins and patient survival. We 
demonstrated that high FILIP1L expression correlates with 
a significantly improved overall survival and disease-free 
survival over a ten-year period post-chemotherapy (Figure 
1E, 1F). Notably, patients with low FILIP1L expression 
showed a median overall survival and disease-free survival 
of 60 and 19 months, respectively, whereas patients with 
high FILIP1L expression had not yet reached median 
overall and disease-free survival at their 120 month follow-
up. When we analyzed for serous ovarian cancer patients 
only, we also demonstrated that high FILIP1L expression 
correlates with a significantly improved overall survival 
and disease-free survival (Supplementary Figure S4). 
Furthermore, patients with a combination of high FILIP1L 
and low β-catenin or SLUG expression had significantly 
longer overall survival than patients with low FILIP1L and 
high β-catenin or SLUG expression (Figure 1E, 1F and 
Supplementary Figure S1E, S1F). The Cox proportional 
hazards model revealed that low FILIP1L expression and 
a combination of low FILIP1L and high SLUG expression 
were independent negative prognostic factors with respect 
to overall survival (Table 2). For disease-free survival, low 
FILIP1L, high SLUG and a combination of low FILIP1L 
and high β-catenin or high SLUG, and of high β-catenin 
and high SLUG expression were independent negative 
prognostic factors (Table 3). Together these results support 
the observation that FILIP1L may be a useful tumor 
marker whose expression is inversely correlated with poor 
prognosis, stage and chemoresistance, possibly due to its 
role in inhibiting WNT/β-catenin pathway.
FILIP1L inhibits ovarian cancer metastases
Having shown in clinical samples that FILIP1L 
expression decreases with tumor progression, we tested 
whether or not re-expression of FILIP1L could inhibit 
ovarian cancer metastases in an orthotopic mouse model. 
Two ovarian cancer cell lines, OVCA429 and SKOV3, 
were engineered to express FILIP1L at levels within 
the same order of magnitude as those in immortalized 
normal ovarian epithelial cells as shown by both mRNA 
and protein expression (Figure 2A), as well as expressing 
near-infrared fluorescent protein 720 (iRFP) [48]. Both 
control and FILIP1L+ clones were orthotopically injected 
into the ovaries of Nude mice and peritoneal metastatic 
spread was monitored by in vivo fluorescence imaging. 
FILIP1L+ derivatives developed markedly reduced 
peritoneal metastases compared to the parental cell lines 
(Figure 2B). As quantified by total radiant efficiency, 
FILIP1L inhibited 16- and 7-fold peritoneal metastases 
of OVCA429 and SKOV3, respectively (Figure 2C). 
As shown in Supplementary Figure S5, doxycycline-
inducible FILIP1L+ clones from an ES2 cell line [39] also 
resulted in a significant reduction in peritoneal metastases, 
compared to the control demonstrating metastatic cancer 
spread into the peritoneum and the surface of visceral 
organs and the diaphragm. These results support our 
findings that FILIP1L is a potent tumor suppressor in 
ovarian cancer.
FILIP1L knockdown induces chemoresistance in 
ovarian cancer cells
As discussed, there is a direct association between 
metastatic potential, EMT and chemoresistance in cancer. 
Figure 1D and Supplementary Figure S1C show that in 
chemoresistant clinical samples, FILIP1L expression 
is decreased significantly, while SLUG expression is 
increased significantly. Thus, we explored the correlation 
between FILIP1L, SLUG and chemoresistance in ovarian 
cancer cells. To this end, we decreased FILIP1L and SLUG 
expression in two ovarian cancer cell lines from high-
grade serous carcinoma [49], the relevant histosubtype for 
chemoresistance [1, 50] using siRNA transfection. FILIP1L 
and SLUG proteins were undetectable by immunoblot at 
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day 2 post-siRNA transfection (Figure 3A). Suppression 
of FILIP1L increased the expression of SLUG, and SLUG 
expression was decreased by co-transfection of siRNAs for 
FILIP1L and SLUG (Figure 3A, third panel). Cells were 
treated with cisplatin, paclitaxel or doxorubicin following 
siRNA transfection. A cytotoxicity assay was used to 
confirm the markedly decreased ability of the three agents 
to kill ovarian cancer cells that no longer express FILIP1L 
(Figure 3B). In order to further prove cause-and-effect, we 
tested if SLUG knockdown can reverse the chemoresistant 
phenotype resulting from FILIP1L knockdown. Indeed, 
this phenotype was rescued by simultaneous knockdown 
of FILIP1L and SLUG (Figure 3C). Additionally, 
FILIP1L-high expressing cells such as HEY and OVCAR8 
were more chemosensitive than FILIP1L-low expressing 
cells such as OVCA429 and SKOV3 (data not shown). 
Overall, our data indicate that chemoresistance is inversely 
correlated with FILIP1L expression and that FILIP1L may 
inhibit SLUG-mediated chemoresistance.
FILIP1L regulates β-catenin degradation, the 
key transcriptional cofactor of WNT signaling
These experiments were directed at further 
elucidating the mechanism of action of FILIP1L. We 
previously showed that FILIP1L reduces nuclear β-catenin 
as well as transcriptional activation of canonical WNT-
target genes. Additionally, we showed that FILIP1L 
localizes in the cytoplasm and centrosomes [39], recently 
identified as the proteolytic centers of the cell [51–54]. 
Table 1: Association of FILIP1L, Beta-catenin, and SLUG expression with clinicopathological 
characteristics in normal and neoplastic ovarian tissue samples
No
FILIP1L Beta–catenin SLUG
Median [IQR] p value Median [IQR p value Median [IQR] p value
Diagnostic category
  Normal 64 88 [50–142] < 0.001 54 [30–89] < 0.001 110 [79–173] < 0.001
  Benign 29 84 [39–140] 66 [34–100] 141 [86–195]
  Borderline 50 59 [29–105] 84 [60–128] 131 [68–183]
  Cancer 182 50 [13–109] 106 [71–150] 144 [91–183]
  Metastatic 46 35 [12–60] 100 [70–131] 224 [162–266]
Age
  ≤ 50 85 56 [18–123] 0.032 110 [59–149] 0.808 146 [99–180] 0.755
  > 50 97 41 [7–85] 99 [74–150] 143 [83–196]
Histological subtype
  Serous 123 50 [17–101] 0.914 101 [73–145] 0.531 146 [86–197] 0.647
  Others 59 55 [7–119] 110 [64–170] 140 [107–165]
FIGO stage
  I/II 48 91 [30–122] 0.007 101 [60–143] 0.535 136 [81–163] 0.102
  III/IV 121 41 [11–76] 101 [74–150] 145 [91–199]
Tumor grade
  Well + Moderate 78 51 [12–110] 0.916 110 [80–161] 0.144 143 [83–179] 0.589
  Poor 91 50 [16–104] 98 [60–143] 140 [91–181]
CA125
  ≤ 35 24 43 [20–130] 0.238 99 [60–134] 0.632 136 [87–155] 0.290
  > 35 154 51 [11–102] 106 [73–151] 145 [91–183]
Chemosensitivity
  Sensitive 152 55 [16–113] 0.002 104 [70–150] 0.182 141 [90–182] 0.041
  Resistant 12 5.5 [0–27] 136 [89–155] 168 [147–190]
aCalculated only 169 cases with available information of FIGO stage and tumor grade.
bCalculated only 178 cases with available information of CA125.
cCalculated only 163 cases with available information of chemosensitivity.
Protein expression was determined through analysis of an immunohistochemically stained tissue array, as described in the 
materials and methods section.
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Figure 1: Expression of FILIP1L, β-catenin and SLUG in normal and cancerous ovarian tissue. (A) Immunohistochemical 
staining of FILIP1L, β-catenin and SLUG was performed on tissue microarray of human ovarian cancer specimens. The final histoscore, 
ranging from 0-300, was calculated by multiplying the intensity by percentage of staining. A. Representative images of immunohistochemical 
staining of FILIP1L, β-catenin and SLUG in ovarian tissues from normal, benign, borderline, and carcinoma patients. High magnification 
images are shown in inset. Scale bar shown is 100 μm. (B) Expression of FILIP1L was analyzed in specimens from normal (n = 64), 
benign (n = 29), borderline (n = 50), epithelial ovarian cancer (n = 123 for Serous type; n = 59 for other histologies) and metastasis 
(n = 46). *, ** and *** indicate P < 0.05, P < 0.01 and P < 0.001, respectively. (C) FILIP1L expression was compared between specimens 
from FIGO stage I/II (n = 48) and stage III/IV (n = 121) ovarian cancers. (D) FILIP1L expression was compared between specimens from 
chemosensitive (n = 152) and chemoresistant (n = 12) ovarian cancer patients. Cancer patients who had recurrence within 6 months after 
platinum and paclitaxel chemotherapy were considered resistant. (E–F) Overall survival (E) and disease-free survival (F) of ovarian cancer 
patients who were positive for FILIP1L was analyzed in Kaplan–Meier plots. Receiver operating characteristic (ROC) analysis was used to 
determine histoscore cut-off values. Histoscore of ≥ 75 for FILIP1L expression was considered high. 
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These observations prompted us to study the effects of 
FILIP1L on β-catenin availability. FILIP1L+ OVCA429 
and SKOV3 clones were treated with a WNT activator 
(LiCl) [55], in the presence or absence of a proteasome 
inhibitor (MG132). We obtained similar results for 
activating WNT signaling using other agents including 
a WNT ligand WNT-3A (R&D systems) and GSK- 3β 
inhibitors such as SB-216763 (Sigma-Aldrich) and 
BIO (Calbiochem) (data not shown). Immunoblotting 
was used to detect levels of phosphorylated-β-catenin 
(inactive; destined for proteasomal degradation), non-
phosphorylated β-catenin (active) and total β-catenin. 
Irrespective of WNT activation, the active β-catenin 
pool was decreased and the inactive pool increased in 
FILIP1L+ cells compared to parental cells (Figure 4A). 
The total β-catenin pool was relatively constant in all 
samples. When cells were treated with MG132, we 
observed increased inactive β-catenin levels. Since this 
phenomenon was independent of FILIP1L, it suggests 
that FILIP1L exerts its effects on β-catenin availability 
upstream of the proteasome. In addition, when FILIP1L 
was decreased using siRNA in FILIP1L-high expressing 
HEY and OVCAR8 cells, the phosphorylated β-catenin 
pool was decreased compared to the non-targeted 
control siRNA-transfected cells (Supplementary Figure 
S6). Next, we fractionated cells into nuclear, cytosolic 
and total cell lysates, and measured the levels of active 
and total β-catenin. As shown in Supplementary Figure 
S7, FILIP1L reduced the active β-catenin pool of 
nuclear and cytosolic fractions. These results were 
further confirmed by immunofluorescence staining. 
Active β-catenin localized in the cytosol, nucleus and 
Table 2: Univariate and multivariate analyses of overall survival in ovarian cancer patients
Univariate analysis Multivariate analysis
Variables Hazard ratio [95% CI] p value Hazard ratio [95% CI] p value
Age (> 50) 2.20 [1.17–4.13] 0.014 2.02 [1.02–3.98] 0.043
FIGO stage (III/IV) 4.72 [1.68–13.24] 0.003 3.15 [1.08–9.18] 0.036
Cell type (non-serous) 0.31 [0.13–0.73] 0.008 0.56 [0.23–1.34] 0.193
Grade (poor) 1.84 [1.00–3.39] 0.049 1.73 [0.90–3.29] 0.098
CA125 (> 35) 1.97 [0.70–5.50] 0.196 NA
FILIP1L- 3.04 [1.46–6.34] 0.003 2.30 [1.03–5.15] 0.043
Beta-catenin+ 0.72 [0.40–1.30] 0.283 NA
SLUG+ 1.80 [0.97–3.34] 0.062 NA
FILIP1L-/Beta-catenin+ 2.80 [0.91–8.63] 0.074 NA
FILIP1L-/SLUG+ 3.08 [1.27–7.47] 0.013 2.77 [1.08 – 7.07] 0.033
Beta-catenin+/SLUG+ 1.36 [0.58–3.18] 0.485 NA
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval; NA, not applicable.
Table 3: Univariate and multivariate analyses of disease-free survival in ovarian cancer patients
Univariate analysis Multivariate analysis
Variables Hazard ratio [95%CI] p value Hazard ratio [95%CI] p value
Age (> 50) 1.62 [1.05–2.48] 0.028 1.46 [0.92–2.30] 0.108
FIGO stage (III/IV) 6.30 [2.90–13.68] < 0.001 4.61 [2.10–10.13] < 0.001
Cell type (non-serous) 0.37 [0.22–0.64] < 0.001 0.63 [0.36–1.12] 0.119
Grade (poor) 1.86 [1.20–2.88] 0.006 1.73 [1.09–2.73] 0.019
CA125 (> 35 U/ml) 1.96 [0.94–4.05] 0.071 NA
FILIP1L- 2.42 [1.49–3.93] < 0.001 2.03 [1.21–3.41] 0.008
Beta-catenin+ 1.32 [0.87–2.00] 0.192 NA
SLUG+ 1.55 [1.01–2.38] 0.044 1.89 [1.20–2.95] 0.006
FILIP1L-/Beta-catenin+ 3.88 [1.78–8.46] 0.001 3.42 [1.53–7.64] 0.003
FILIP1L-/SLUG+ 2.41 [1.34–4.34] 0.003 2.52 [1.36–4.65] 0.003
Beta-catenin+/SLUG+ 1.97 [1.09–3.56] 0.024 2.76 [1.44–5.32] 0.002
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval; NA, not applicable.
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cell membrane of control cells, and was significantly 
decreased in all of these compartments in FILIP1L-
expressing cells (Figure 4B). FILIP1L expression 
and WNT signaling activation did not modulate 
β-catenin at the transcriptional level, as confirmed by 
qRT-PCR (data not shown). WNT ligand engagement 
results in phosphorylation of its receptor, LRP5/6. FILIP1L 
expression did not affect LRP5/6 phosphorylation (data 
not shown), which suggests that FILIP1L inhibits WNT 
signaling downstream of receptor activation. Collectively, 
these results suggest that FILIP1L decreases the pool of 
active β-catenin by targeting it for degradation.
Figure 2: The effect of FILIP1L expression on the metastatic potential of ovarian cancer cell lines in a mouse model. 
(A) FILIP1L mRNA levels were determined by qRT-PCR in immortalized normal IOSE cell lines and ovarian cancer cell lines that 
express high FILIP1L (OVCAR8 and HEY). Also shown are low FILIP1L-expressing OVCA429 and SKOV3 ovarian cancer cells, and 
their FILIP1L+ derivatives. The y axis represents FILIP1L mRNA expression standardized for the housekeeping gene RPL7. The result 
is an average of three independent experiments. Immunoblot analysis for FILIP1L in ovarian cells is also shown. Note that the FILIP1L 
band in FILIP1L+ OVCA429 and SKOV3 cells migrates slower than the other untransfected cells because it is expressed as a fusion 
protein with GFP. GAPDH blot is shown as the loading control. (B) OVCA429 (106) and SKOV3 (5 × 105) (CTL) and their FILIP1L+ 
derivatives (FILIP1L) were orthotopically injected into the ovaries of Nude mice. Development of peritoneal metastasis was monitored by 
IVIS imaging, every 3–4 days for a total of 63 and 20 days for OVCA429 and SKOV3, respectively. Representative images at the time of 
sacrifice are shown. The first mouse in each series is the negative control. (C) Time course of quantified metastatic tumor growth (8 mice 
per group). The y axis represents total radiant efficiency ([photons/s]/[μW/cm2]) emitted by iRFP. *,** and ∆ indicate P < 0.05, P < 0.01 
and NS, respectively. The result is representative of two independent experiments.
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Figure 3: Effects of FILIP1L and an EMT activator on chemoresistance in ovarian cancer cells. (A) Knockdown of FILIP1L 
and SLUG was achieved by transient transfection of indicated siRNA. Protein knockdown was shown by immunoblotting. GAPDH blot 
shown underneath of each blot is the loading control. The result is representative of two independent experiments. (B) Cells were treated 
with indicated siRNA for 2 days, and with chemotherapy agents of indicated concentration for an additional day. Cell proliferation was 
measured by WST1 incorporation quantified at OD
440-650nm
. The y axis represents cell proliferation in the presence of drug as a percentage 
of untreated control. (C) The same experimental procedures were used as described in section B with indicated siRNA treatment but only 
30 μM cisplatin, 20 nM paclitaxel or 30 μM doxorubicin were used. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and 
P < 0.0001, respectively. The result is an average of three independent experiments.
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FILIP1L co-localizes with inactive β-catenin and 
proteasomes at the centrosomes
Similar to FILIP1L [39], N-terminally phosphory-
lated β-catenin also localizes in centrosomes [56–58]. To 
investigate whether or not FILIP1L enhances degradation 
of phosphorylated β-catenin, we followed its cellular 
localization by immunofluorescence staining in OVCA429 
and SKOV3 clones. As shown previously in ES2 cells [39], 
FILIP1L was distinctively localized to the centrosomes 
in FILIP1L+ clones from OVCA429 and SKOV3 cells, 
whereas endogenous FILIP1L was barely detectable 
in control clones (first columns of Figure 5A and 5B). 
Inactive β-catenin was present at higher levels in FILIP1L-
expressing cells than in control cells (Figure 5A, 5B), and 
co-localized with FILIP1L (Figure 5B) and the centrosomal 
marker, γ-tubulin (Figure 5C). Moreover, FILIP1L 
co-localized with proteasomes in centrosomes (Figure 5D). 
Next, we quantified the amount of inactive β-catenin at the 
centrosomes. Inactive β-catenin was decreased following 
WNT activator (LiCl) treatment (Figure 5E, 5F). Irrespective 
of WNT activation, the inactive β-catenin pool was increased 
in FILIP1L+ cells compared to parental cells (Figure 5E, 5F). 
Together, our data strongly suggest that FILIP1L facilitates 
the degradation of phospho-β-catenin by proteasomes in 
centrosomes, thereby blocking WNT signaling.
FILIP1L regulates EMT
The WNT signaling induces EMT in ovarian 
cancer. [8, 12]. EMT results in repression of epithelial 
markers such as E-cadherin, and induction of 
mesenchymal markers, including adhesion molecules, 
metalloproteinases (MMPs) and transcriptional factors 
[16, 18]. A key feature of EMT is the loss of epithelial 
surface marker E-cadherin, and its down-regulation is 
often associated with transcriptional repression by EMT 
transcription factors such as SLUG [16, 18]. FILIP1L 
Figure 4: Effect of FILIP1L on β-catenin degradation by proteasomes. (A) Parental and FILIP1L+ OVCA429 and SKOV3 
clones were treated with solvent or 40 mM LiCl for 24 h (WNT+). Cell lysates were immunoblotted with antibodies against inactive 
phospho-β-catenin, active non-phospho-β-catenin, and total β-catenin. The experiment was also performed in the presence of 5 μM MG132 
(proteasome-). GAPDH blot is shown as the loading control. (B) FILIP1L reduces active β-catenin. OVCA429 and SKOV3 clones were 
immunofluorescently stained for active β-catenin (red) and nuclei counterstained with DAPI (blue). Red only and merged images are 
shown. The result is representative of three independent experiments.
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increases β-catenin degradation, which in turn inhibits 
WNT signaling. Our clinical and cellular data indicating 
potential associations between FILIP1L and SLUG led 
us to hypothesize that FILIP1L blocks EMT in ovarian 
cancer by virtue of decreasing the pool of active β-catenin. 
To unravel the possible connection between FILIP1L and 
EMT, the expression of EMT markers was examined 
following WNT signaling activation. First, we tested if 
low FILIP1L-expressing OVCA429 and SKOV3 cells 
acquired a more epithelial phenotype when engineered 
Figure 5: FILIP1L increases inactive β-catenin at centrosomes. (A–B) OVCA429 and SKOV3 clones were immunofluorescently 
stained for FILIP1L (red) and inactive β-catenin (green). Staining is shown in either control (A) or FILIP1L-expressing (B) clones. (C–D) 
FILIP1L-expressing clones were immunofluorescently stained for inactive β-catenin (red) and γ-tubulin (green) (C) and for proteasome 
19S-S7 subunit (red) and FILIP1L (green) (D). Nuclei were counterstained with DAPI (blue). Merged images are also shown. (E–F) The 
quantified data from 200-250 cells is also shown. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively. 
The result is an average of three independent experiments.
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to express FILIP1L. Treatment of these cells with a 
WNT activator (LiCl) significantly decreased E-cadherin 
while increasing expression of mesenchymal markers. In 
contrast, FILIP1L+ clones are characterized by increased 
E-cadherin expression and a simultaneous decrease in 
levels of EMT transcription factors as well as mesenchymal 
markers (Figure 6A). Expression of FILIP1L largely 
abrogated the effects of LiCl-induced WNT signaling as 
evidenced by a reappearance of E-cadherin and repression 
of mesenchymal markers (Figure 6A). Protein expression 
of representative markers confirmed the inhibition of EMT 
by FILIP1L (Figure 6B). We also analyzed EMT marker 
expression in the primary tumors from orthotopic mouse 
models that we procured from the experiments shown 
in Figure 2B. As shown in Supplementary Figure S8, 
tumors from FILIP1L+ clones demonstrated decreased 
expression of mesenchymal markers as well as increased 
E-cadherin expression compared to those from control 
clones. Although the data from mouse tumors showed a 
trend towards EMT inhibition by FILIP1L, they were not 
completely correlated with those from cultured cells. For 
example, although expression of mesenchymal markers 
such as N-cadherin was significantly reduced, E-cadherin 
expression was not increased in FILIP1L+ tumors 
derived from OVCA429 cells. Among the mesenchymal 
markers, SLUG was consistently reduced in FILIP1L+ 
tumors from all three cell lines. We then confirmed 
the differential expression of adhesion markers at the 
protein levels using immunofluorescence staining, where 
N-cadherin expression was decreased significantly in 
FILIP1L+ OVCA429-tumors but E-cadherin expression 
was increased significantly in FILIP1L+ SKOV3 and ES2-
tumors (Supplementary Figure S8).
Next, we tested if high FILIP1L-expressing HEY and 
OVCAR8 cells acquired a more mesenchymal phenotype 
when engineered to knockdown FILIP1L. FILIP1L 
knockdown in these cell lines resulted in increased expression 
of mesenchymal markers but decreased expression of 
E-cadherin (Figure 6C). Interestingly, among the mesenchymal 
markers, SLUG demonstrated a consistent increase following 
FILIP1L knockdown as well as a consistent induction 
following WNT activation in both cell lines. Increased 
expression of mesenchymal markers was accompanied 
by morphological changes where clustered epithelial-like 
cells became scattered spindle-shaped mesenchymal-like 
cells when FILIP1L was knocked down (Figure 6D). These 
morphological changes were reverted by simultaneous 
knockdown of FILIP1L and SLUG (Figure 6D), supporting 
the notion that FILIP1L exerts its anti-tumor activity by 
suppressing SLUG-mediated EMT in ovarian cancer cells.
DISCUSSION
High mortality rate in ovarian cancer is mainly 
due to the fact that most patients are diagnosed with 
advanced stage disease with metastatic spread and that the 
majority of them succumb to recurrent, chemoresistant 
tumors. WNT/β-catenin signaling and its downstream 
target pathway EMT play a key role in ovarian cancer 
progression and chemoresistance [7–9,25]. Our data 
support an important role for FILIP1L in the control of 
this process.  FILIP1L facilitates β-catenin degradation, 
thereby down-regulating EMT in ovarian cancer cells. 
FILIP1L expression is significantly decreased in metastatic 
as well as in chemoresistant clinical samples. Further, 
FILIP1L expression is inversely correlated with stage 
and poor prognosis. While our studies implicate FILIP1L 
from a mechanistic perspective as an important regulator 
of β-catenin at the protein level, these observations 
may also provide an important utility for FILIP1L as 
a clinical biomarker.  The results we have presented 
suggest that the utility of determining FILIP1L expression 
in patients’ samples could provide important prognostic 
information as high levels correlate with a good prognosis 
and lower probability of recurrence in ovarian cancer. This 
could allow the selection of patients with high FILIP1L 
expressing tumors who would be able to avoid over-
intensive chemotherapy and its associated toxicities while 
focusing on patients with low expressing FILIP1L tumors 
who would most benefit from intensive chemotherapy 
regimens. This observation needs to be confirmed in a 
larger prospective cohort of patients.
As shown in the present study, the tumor 
suppressor FILIP1L is down-regulated in metastatic 
and chemoresistant ovarian cancer patient samples. 
Epigenetic regulators of tumor suppressors, including 
DNA methylation, histone modification and micro 
(mi) RNAs play a prominent role in cancer recurrence 
[59– 66]. We previously demonstrated significantly 
increased methylation of FILIP1L promoter residues in 
a region that also comprises a CREB/ATF binding site. 
CpG methylation was on average 10-fold higher in ovarian 
cancer cell lines compared to primary cells, and almost 
2-fold higher in invasive serous carcinomas compared to 
borderline tumors. Methylation was inversely correlated 
with FILIP1L mRNA and protein levels, which were 
restored by a DNA demethylating agent [40]. We noted 
that treating ovarian cancer cell lines with a histone 
deacetylase inhibitor did not change FILIP1L mRNA and 
protein levels in these cell lines, leading us to conclude 
that histone acetylation was not a major epigenetic 
regulator of FILIP1L. To date, no studies have documented 
miRNAs that regulate FILIP1L expression by binding 
to 3ʹ untranslated regions (UTR). Thus it will be an 
important next step to identify the regulatory mechanisms 
by which FILIP1L is down-regulated in metastatic and 
chemoresistant samples.
In the present study, we show that FILIP1L 
colocalizes with phospho-β-catenin and proteasomes 
in centrosomes, the proteolytic center of the cell [51–54] 
and that phospho-β-catenin in centrosomes was reduced 
by FILIP1L following WNT signaling activation. These 
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Figure 6: Regulation of EMT markers by WNT signaling and FILIP1L. (A) Parental or FILIP1L+ OVCA429 clones were 
treated with solvent or 40 mM LiCl for 24 h (WNT+). mRNA levels of EMT markers were measured by qRT-PCR. The y axis represents 
fold change over the control (solvent-treated parental cells). Each value was also standardized for the housekeeping gene GAPDH. The 
result is an average of three independent experiments. (B) Immunoblot analysis for the indicated EMT markers from OVCA429 and 
SKOV3 clones treated with the same methods as in section A. GAPDH blot is shown as the loading control. Values indicate the quantified 
each protein amount normalized to the loading control GAPDH. Note that endogenous E-cadherin protein levels could not be detected 
due to low levels of expression in SKOV3 cells. The result is representative of three independent experiments. (C) HEY and OVCAR8 
cells were treated with either non-targeting or FILIP1L siRNA, and with solvent or 40 mM LiCl for 24 h (WNT+). mRNA levels of EMT 
markers were measured as described in section A. The result is an average of three independent experiments. (D) HEY and OVCAR8 cells 
were treated with indicated siRNA for 2 days and cell morphology was imaged with light microscope. *, **, ***, **** and ∆ indicate 
P < 0.05, P < 0.01, P < 0.001, P < 0.0001 and NS, respectively.
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findings indicate that FILIP1L inhibits WNT signaling 
by facilitating degradation of phospho-β-catenin in 
centrosomes. The concept that centrosomal proteins 
antagonize WNT signaling in cancer cells establishes a 
new paradigm for tumor suppression. Figure 7 illustrates 
our proposed mechanism that FILIP1L facilitates phospho-
β-catenin degradation through the ubiquitin-proteasome 
system in the centrosomes. This results in inhibition of 
β-catenin-dependent transcriptional regulation of various 
pathways that facilitate metastasis and chemoresistance, 
such as EMT.
We originally identified FILIP1L in angiogenesis 
setting. FILIP1L was shown to be specifically up-regulated 
in endothelial cells following the treatment of angiogenesis 
inhibitors [67, 68]. We then showed that FILIP1L 
expression in endothelial cells led to decreased cell 
migration and increased apoptosis, and that tumor vessel-
expression of FILIP1L blocked in vivo tumor growth [42]. 
These data suggest that FILIP1L may be considered as an 
anti-angiogenic therapeutic. As anti-angiogenic strategy 
such as anti-VEGF therapy is another potential treatment 
in ovarian cancer, it potentiates the possibility of FILIP1L 
being a therapeutic target in ovarian cancer. 
Ovarian carcinomas are heterogeneous, consisting 
of at least five different subtypes: high-grade serous (most 
prevalent), low-grade serous, mucinous, endometrioid and 
Figure 7: The proposed role of FILIP1L in inhibiting cancer cell invasion and metastasis through inhibition of 
WNT signaling. Newly synthesized β-catenin is immobilized by E-cadherin at adherens junctions [10]. β-catenin can be released 
from the adherens junctions by downregulation of E-cadherin or by the activity of protein kinases. Free excess β-catenin is immediately 
phosphorylated by the destruction complex and thus marked for subsequent degradation. Canonical WNT signaling blocks the activity of 
the destruction complex resulting in increased levels of cytolasmic β-catenin, which is translocated to the nucleus. In the nucleus, β-catenin 
induces the expression of WNT target genes: 1) the transcription factors that repress the expression of E-cadherin; 2) MMPs that cleave 
E-cadherin as well as extracellular matrix (ECM); 3) the ECM and integrin molecules that favor cell-ECM adhesion. These events lead to 
induction of EMT. FILIP1L enhances β-catenin degradation in centrosomes possibly through: 1) inactivating the component(s) of β-catenin 
destruction complex, i.e. inactivating kinase activity of CK1 or GSK3β; 2) facilitating phospho-β-catenin recruitment into centrosomes; 3) 
facilitating polyubiquitination of phospho-β-catenin; 4) facilitating proteasome-mediated phospho-β-catenin degradation downstream of 
polyubiquitination. Downstream signaling of active β-catenin (via transcriptional regulation) is thus decreased.
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clear cell [50]. It was shown in ovarian cancer, mainly in 
endometrioid subtype that β-catenin mutants, resulting 
from activating and missense mutations, became resistant 
to proteosomal degradation [69]. Accumulating data 
indicate that although mutations in β-catenin and other 
genes in the WNT pathway are rare in other ovarian 
cancer subtypes than endometrioid, the WNT signaling 
plays a role in carcinogenesis of all subtypes of ovarian 
cancer [5– 7]. Increased β-catenin levels are commonly 
observed in different ovarian cancer subtypes and correlate 
with cancer stage and poor survival [6, 11–14]. This is 
consistent with our data where we have observed that the 
expression of FILIP1L, β-catenin and SLUG between 
serous and other subtypes are similar. These results are 
also supported by previous reports that have shown that 
the expression level of β-catenin and SLUG was similar 
between serous and other subtypes [14, 70, 71]. We 
speculate that FILIP1L may exert its tumor-suppressor 
activity by degrading increased β-catenin regardless of 
ovarian cancer subtype.
Although master EMT-regulating transcription 
factors SLUG and SNAIL [72] were shown to be directly 
associated with cisplatin and paclitaxel resistance in 
ovarian cancer [46, 47], SLUG but not SNAIL was 
consistently modulated by FILIP1L in our in vitro, in 
vivo and clinical specimen data. Induction of SLUG 
was consistently inhibited by FILIP1L following WNT 
signaling activation in several ovarian cancer cell lines 
tested. Simultaneous knockdown of SLUG reversed 
the chemoresistant as well as EMT phenotypes that 
had resulted from knockdown of FILIP1L. FILIP1L 
expression is decreased significantly, while SLUG 
expression is increased significantly, in chemoresistant 
clinical samples. In addition, the expression of FILIP1L 
was negatively correlated with the expression of SLUG 
in clinical samples, suggesting a link between FILIP1L 
and the SLUG-mediated EMT pathway in ovarian cancer. 
In the canonical WNT pathway, β-catenin is the crucial 
mediator responsible for the downstream transcriptional 
regulation [10]. The final transcriptional products are 
controlled by networking with other transcription factors 
in a context-dependent manner [10]. Our data suggest 
that expression of various EMT markers including EMT-
regulating transcription factors can vary depending on 
cell lines, in vitro vs. in vivo, etc. Regardless, SLUG 
seems to be a consistent central downstream target for 
the FILIP1L-modulated WNT pathway in ovarian cancer. 
Future experiments employing ChIP-Seq and RNA-Seq 
analyses from FILIP1L-knockdown cells and tumors, will 
help identify key downstream target(s) of EMT.
In addition to activating EMT, β-catenin directly 
regulates the transcription of ATP-binding cassette (ABC) 
transporter genes such as ABCG2/BCRP and ABCB1/
MDR1 in ovarian cancer [73,74]. ABC transporters have 
been implicated in chemoresistance and suggested as novel 
targets for treating cancer recurrence [75]. Isoliquiritigenin 
has been shown to augment chemosensitivity by targeting 
the β-catenin-mediated induction of ABCG2 in breast cancer 
[76]. Thus, it will be of interest to test if FILIP1L inhibits 
ABC transporter(s)-driven chemoresistance. However, 
as an immediate translational observation, determination 
of FILIP1L expression levels in patient tumors may be 
helpful in identifying those patients that are likely to be 
chemosensitive versus those that will be more resistant.
In summary, we have shown that FILIP1L 
expression is related with inhibition of metastases 
and chemoresistance, which is associated with down-
regulation of EMT through β-catenin degradation. 
FILIP1L expression correlates with significantly improved 
overall survival, and is an independent prognostic factor 
for overall and disease-free survival in ovarian cancer. 
Further characterization of the mechanism of action of 
FILIP1L on chemosensitivity may help elucidate the role 
played by FILIP1L in ovarian cancer recurrence and result 
in the development of more effective treatment regimens. 
Since FILIP1L expression is inversely correlated with 
cancer invasiveness/aggressiveness in various other cancer 
types [39–41], these studies will also have an impact on 
treatment of other cancers.
MATERIALS AND METHODS
Tissue microarray and immunohistochemistry
A total of 64 normal epithelial tissues, 29 benign 
tumors (19 serous and 10 mucinous), 50 borderline tumors 
(21 serous, 24 mucinous, 1 clear cell and 4 mixed), 182 
epithelial ovarian cancers (123 serous, 14 mucinous, 
26 endometrioid, 10 clear cell, 7 transitional cell and 
2 mixed) and 46 metastatic tumors were selected from 
patients who enrolled in the Gangnam Severance Hospital 
and the Korea Gynecologic Cancer Bank between 1996 
and 2010. Some of the paraffin blocks were provided 
by the Korea Gynecologic Cancer Bank through the 
Bio and Medical Technology Development Program 
of the Ministry of Education, Science and Technology, 
Korea (NRF-2012M3A9B8021800). Ovarian cancer 
was staged according to the International Federation of 
Gynecology and Obstetrics (FIGO) staging system and 
graded according to the WHO grading system. The age of 
patients ranged from 22 to 80 years (average 52.3 years). 
Twelve patients presented with early recurrence during or 
within 6 months of initial treatment, which were grouped 
as a chemoresistant cases based on the clinical definition 
of chemoresistance to platinum in ovarian cancer. 
Tissue microarrays (TMAs) were produced 
from formalin-fixed, paraffin-embedded tissues, and 
representative areas were meticulously selected from 
hematoxylin and eosin stained slides. Tissue cylinders 
of 1.0 mm diameter were extracted from selected areas 
of donor blocks and transplanted into recipient blocks 
using a tissue arrayer (Beecher Instruments). Tissue 
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samples and medical records were obtained with informed 
consent of all patients and approval of the local research 
ethics committee (approval no. 2015–07–122; Seoul, 
South Korea). This study was additionally approved by 
the Office of Human Subjects Research at the National 
Institutes of Health.
For immunohistochemical staining, all paraffin 
sections were cut to 5 μm thickness, deparaffinized 
through xylene, and dehydrated through graded ethanol 
series. Antigen recovery was performed in heat-activated 
antigen retrieval buffer pH 6.0 (Dako). Endogenous 
peroxidase activity was blocked by addition of 3% H2O2. 
For FILIP1L, additional protein blocker (Dako) was 
applied. The slides were incubated at room temperature 
with antibodies against FILIP1L, β-catenin, SLUG and 
SNAIL. Antibodies are described in Supplementary 
Table S2. The antigen-antibody reaction was detected with 
EnVision+ Dual Link System-HRP and visualized with 
DAB+ (3, 3′-Diaminobenzidine; Dako). 
The evaluation of immunostaining was carried 
out using computer-assisted image analyzing software 
version 4.5.1.324 (Visiopharm). Immunohistochemically 
stained slides were scanned using NanoZoomer 2.0 HT 
(Hamamatsu Photonics) at ×20 objective magnification 
(0.5 μm resolution), and captured digital images were then 
imported into the Visiopharm software. The threshold for 
size and shape of tumor cells was manually calibrated. 
Briefly, brown-colored (DAB-stained) and blue-colored 
(hematoxylin-stained) cells were separated spectrally. 
A brown staining intensity (0 = negative, 1 = weak, 
2 = moderate and 3 = strong) was obtained using a 
predefined algorithm and optimized settings.  The final 
histoscore was calculated by multiplying the intensity and 
percentage of staining resulting in score of 0 to 300 as 
described previously [77, 78]. The cut-off value of histoscore 
for discriminating between low and high expression was 
determined through receiver operating characteristic (ROC) 
analysis as described previously [79, 80]. 
Cell culture and development of stable clones 
expressing FILIP1L
Human ovarian cancer cell lines ES2 and SKOV3 
were purchased from American Type Culture Collection 
(ATCC) (Manassas). OVCA429 was provided by Dr. 
Barbara Vanderhyden (University of Ottawa), and HEY 
and OVCAR8 were provided by Dr. Gloria Huang (Albert 
Einstein College of Medicine) as described previously 
[40]. STR profiling of these cell lines were performed 
in March 2016 by the Genomics Core Facility at Albert 
Einstein College of Medicine using the Geneprint 10 
kit (Promega).  Cell suspensions were spotted on FTA 
cards and processed with an ABI 3730 DNA Analyzer. 
The alleles were analyzed by GeneMarker Software 
(SoftGenetics) and the allele reports (Supplementary 
Table S1) were compared with the ATCC Database or the 
published data [81]. 
FILIP1L-expressing OVCA429 and SKOV3 clones 
were developed as follows. Cells were transfected with 
piRFP-720 vector [48] followed by Neomycin selection. 
Resistant cells were then transfected with p110-GFP alone 
(GeneCopoeia) or encoding FILIP1L-GFP, followed by 
the selection of both Zeocin and fluorescence-activated 
cell sorting (FACS) for GFP. FILIP1L expression was 
tested by both qRT-PCR and immunoblot.
Ovarian orthotopic model and IVIS imaging
All use of vertebrate animals described in this study 
was conducted in accordance with NIH regulations and 
was approved by the Animal Use Committee of Albert 
Einstein College of Medicine. Control or FILIP1L clones 
from each cell lines were injected under the bursal 
membrane of ovary in 8 week-old female nude mice 
(National Cancer Institute). Experimental details were 
followed as described previously [39]. For ES2 cells, 
mice were sacrificed at day 19 after orthotopic injection 
and metastatic tumor growth was quantified by weighing 
macroscopic metastatic tumors throughout peritoneal 
organs. For OVCA429 and SKOV3 clones that express 
iRFP (infra-red fluorescent protein; [48]), peritoneal tumor 
growth was monitored by in vivo imaging system (IVIS; 
LI-COR) as recommended by the manufacturer. Far red 
fluorescence was measured with excitation at 710 nm 
and emission at 760 nm, and total radiant efficiency was 
calculated with LivingImage software (LI-COR).
SiRNA transfection
ON-TARGETplus Non-Targeting siRNA Pool 
(D-001810-10), FILIP1L siRNA (#7 (J-019458-07) 
and SMARTpool (set of 4 sequences; L-019458-00)) 
and SLUG siRNA (#8 (J-017386-08) and SMARTpool 
(L-017386-00)) were purchased from Thermo Scientific. 
HEY and OVCAR8 cells were transfected with equimolar 
amounts of either non-Targeting or FILIP1L and/or 
SLUG siRNA using Dharmafect solution following the 
manufacturer’s protocols (Thermo Scientific). After a 48 h 
transfection, the cell lysates were subjected to qRT-PCR 
and immunoblot analysis.
Immunoblot
Experimental details were followed as described 
previously [39]. For the preparation of cell fractionation, 
NE-PER nuclear and cytoplasmic extraction kit (Thermo 
Scientific) was used. Protein quantification from 
immunoblot was performed using AlphaView SA software 
(ProteinSimple).
Quantitative real-time RT-PCR
Total RNA preparation and qRT-PCR was 
performed as described previously [40]. The gene-specific 
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primers used with SYBR Green reagent are described in 
Supplementary Table S2. ITGB3 primers were purchased 
from Qiagen.
WST1 cell proliferation assay
SiRNA-transfected cells were seeded in 96-well 
plates, treated with cisplatin, paclitaxel and doxorubicin 
for 24 h and incubated with WST1 (Roche) for 2 h. Cell 
proliferation by WST1 incorporation was measured using 
a Synergy Mx microplate reader (Biotek).
Immunofluorescence staining
Experimental details were followed as described 
previously [39]. Images were acquired by an AxioCam 
HRM camera (Yokogawa) at 63× objective magnification 
(z stack of 0.4 μm thickness) on a Spinning disc confocal 
microscope (Zeiss; Observer Z1). Acquired images were 
then analyzed by AxioVision LE software (Zeiss). To 
quantify inactive β-catenin-, E-cadherin- or N-cadherin-
positive signals, Cell Profiler software [82] was used as 
described previously [39].  
Statistical analysis
Statistical analysis for tissue microarray data was 
performed using R software package (version 3.1.2). 
The Mann-Whitney U-test was used to compare the 
protein expressions between each group. Analysis of the 
Spearman’s rho coefficient was used to assess correlations 
between parameters. Survival distributions were estimated 
using the Kaplan-Meier method with the log-rank test. A 
Cox proportional hazards model was created to identify 
independent predictors of survivals. For the rest of 
experiments, data are presented as the mean ± SEM for 
the indicated number of separate experiments. Statistical 
analyses were performed using a two-tailed Student›s t test 
(GraphPad Prism 3.0), and differences were considered 
statistically significant at P < 0.05. 
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